垂体前叶功能减退症 中国就医指南

Anterior pituitary hypofunction, also known as hypopituitarism, is a clinical endocrine disorder characterized by partial or complete deficiency in the secretion of one or more hormones produced by the anterior lobe of the pituitary gland—including growth hormone (GH), thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin (PRL). This condition arises not from intrinsic hypothalamic dysfunction but from structural damage, vascular compromise, inflammatory infiltration, or genetic defects affecting the anterior pituitary parenchyma or its blood supply. Common pathogenic mechanisms include pituitary adenomas (especially non-functioning macroadenomas compressing normal tissue), postpartum pituitary necrosis (Sheehan syndrome), traumatic brain injury, radiation therapy to the sellar region, autoimmune lymphocytic hypophysitis, infiltrative diseases (e.g., sarcoidosis, hemochromatosis), and congen (e.g., PROP1, POU1F1). Epidemiologically, the estimated prevalence is approximately 3 per 100,000 individuals, with an annual incidence of 4–6 new cases per million. It affects both sexes equally and can occur at any age, though diagnosis peaks in the fourthoften delayed due to insidious, nonspecific symptom onset. Key risk factors include prior neurosurgery or cranial radiotherapy, history of severe obstetric hemorrhage, autoimmune polyglandular syndromes, head trauma with skull familial genetic predisposition. Clinical manifestations depend on the specific hormonal deficits: ACTH deficiency causes fatigue, hypotension, hyponatremia, and life-threatening adrenal crisis; TSH deficiency leads to cold intolerance, weight gain, bradycardia, and cognitive slowing; GH deficiency in adults contributes to reduced lean body mass, increased visceral adiposity, dyslipidemia, and impaired quality of life; gonadotropin deficiency results in amenorrhea, infertility, decreased libido, and erectile dysfunction; and prolactin deficiency may impair lactation postpartum. Untreated or suboptimally managed anterior pituitary hypofunction significantly impairs physical functioning, emotional well-being, social engagement, and occupational performance. Patients frequently report chronic fatigue, depression, and reduced resilience to physiological stressors—factors that collectively diminish health-related quality of life (HRQoL) scores across validated metrics such as SF-36 and QoL-HA. Early diagnosis via dynamic endocrine testing (e.g., insulin tolerance test, corticotropin-releasing hormone stimulation, GHRH-arginine test) and MRI of the sella turcica is critical. Lifelong, individualized hormone replacement remains the cornerstone of management, requiring careful titration, regular monitoring of serum hormone levels and metabolic parameters, and patient education on sick-day rules and emergency glucocorticoid administration.

# 垂体前叶功能减退症治疗方案与费用明细（内分泌科）

一、非手术保守治疗（一线方案）

适用于确诊后激素缺乏明确、无占位性病变者。

• •糖皮质激素替代：氢化可的松（基础剂量），月均药费：200–600元；泼尼松片（经济替代），月均：30–120元
• •甲状腺激素替代：左甲状腺素钠片（优甲乐），月均：30–90元
• •性激素替代（如适用）：睾酮凝胶/雌二醇贴片，月均：400–1500元
• •生长激素替代（儿童/青年严重GHD）：重组人生长激素（国产/进口），年均：3.6万–12万元
• •配套检查费（每年2次）：垂体激素全套（ACTH、TSH、GH、IGF-1、LH/FSH、PRL、睾酮/雌二醇）、肝肾功、骨密度，合计：1800–3200元

二、手术治疗方案

仅适用于继发于垂体大腺瘤、卒中或压迫致进行性减退者，需神经外科联合评估。

• •经鼻蝶窦垂体瘤切除术（微创）：术前垂体MRI+动态增强+视力视野检查，费用：2800–4500元；手术及住院（7–10天）：4.2万–7.8万元（含麻醉、ICU监护、术后激素过渡管理）

三、复杂/晚期/并发症方案

• •垂体危象抢救（肾上腺危象）：急诊静脉氢化可的松+补液支持，单次抢救费用：3500–8200元
• •多腺体功能衰竭合并骨质疏松/垂体性矮小：联合骨科/儿科会诊，年度综合管理费（含DHEA、GH调整、骨折预防）：5.5万–14万元

方案快速选择指南

✅ 初诊稳定型：首选保守替代治疗（年总成本约0.8万–2.5万元） ✅ 预算有限者：选用国产激素+基层随访，年支出≤0.6万元 ✅ 肿瘤继发者：必须手术+术后终身替代，首年投入≥8万元 ✅ 危象高风险者（既往昏迷史）：建议配备应急氢化可的松注射剂（自备），加购医疗绿色通道服务（年费1200元）